Remyelination varies between and within lesions in multiple sclerosis following bexarotene.

ABSTRACT:

Objective

In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, or even reverse, disability. We recently trialled bexarotene versus placebo in 49 people with multiple sclerosis. While the primary MRI outcome was negative, there was converging neurophysiological and MRI evidence of efficacy. Multiple factors influence lesion remyelination. In this study we undertook a systematic exploratory analysis to determine whether treatment response - measured by change in magnetisation transfer ratio - is influenced by location (tissue type and proximity to CSF) or the degree of abnormality (using baseline magnetisation transfer ratio and T1 values).

Methods

We exa

SUBMITTER: Brown JWL 

PROVIDER: S-EPMC9539389 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature